The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies - PubMed

Review

The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies

Nico J Diederich et al. Neurology. 2008.

Abstract

Placebo (PL) treatment is a method utilized as a control condition in clinical trials. A positive placebo response is seen in up to 50% of patients with Parkinson disease (PD), pain syndromes, and depression. The response is more pronounced with invasive procedures or advanced disease. Physiologic and biochemical changes have been studied in an effort to understand the mechanisms underlying placebo-related clinical improvement. In PD, objective clinical improvements in parkinsonism correlate with dopaminergic activation of the striatum, documented by PET and with changes in cell firings of the subthalamic nucleus documented by single cell recordings. Dopaminergic pathways mediating reward may underlie PL-mediated improvement in PD. In pain syndromes, endogenous opioid release triggered by cortical activation, especially the rostral anterior cingulated cortex, is associated with PL-related analgesia and can be reversed by opioid antagonists. Covert treatment of an analgesic is less effective than overt treatment, suggesting an expectation component to clinical response. In depression, PL partially imitates selective serotonin reuptake inhibitor-mediated brain activation. Diseases lacking major "top-down" or cortically based regulation may be less prone to PL-related improvement.

Comment in

• The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies.

  Oken BS. Oken BS. Neurology. 2009 Jun 9;72(23):2053; author reply 2053-4. doi: 10.1212/01.wnl.0000349697.25117.41. Neurology. 2009. PMID: 19506232 No abstract available.

Similar articles

• Effects of expectation on placebo-induced dopamine release in Parkinson disease.

  Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernández R, Phillips AG, Stoessl AJ. Lidstone SC, et al. Arch Gen Psychiatry. 2010 Aug;67(8):857-65. doi: 10.1001/archgenpsychiatry.2010.88. Arch Gen Psychiatry. 2010. PMID: 20679593

• Placebo mechanisms and reward circuitry: clues from Parkinson's disease.

  de la Fuente-Fernández R, Schulzer M, Stoessl AJ. de la Fuente-Fernández R, et al. Biol Psychiatry. 2004 Jul 15;56(2):67-71. doi: 10.1016/j.biopsych.2003.11.019. Biol Psychiatry. 2004. PMID: 15231437 Review.

• The placebo-reward hypothesis: dopamine and the placebo effect.

  de la Fuente-Fernández R. de la Fuente-Fernández R. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S72-4. doi: 10.1016/S1353-8020(09)70785-0. Parkinsonism Relat Disord. 2009. PMID: 20083013

• The placebo response: neurobiological and clinical issues of neurological relevance.

  Pollo A, Benedetti F. Pollo A, et al. Prog Brain Res. 2009;175:283-94. doi: 10.1016/S0079-6123(09)17520-9. Prog Brain Res. 2009. PMID: 19660663 Review.

• [Placebo effect in Parkinson's disease].

  Miwa H. Miwa H. No To Shinkei. 2007 Feb;59(2):139-46. No To Shinkei. 2007. PMID: 17315755 Review. Japanese.

Cited by

• Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.

  Gu SC, Ye Q, Wang CD, Zhao SR, Zhou J, Gao C, Zhang Y, Liu ZG, Yuan CX. Gu SC, et al. Front Pharmacol. 2022 Feb 25;13:739194. doi: 10.3389/fphar.2022.739194. eCollection 2022. Front Pharmacol. 2022. PMID: 35281890 Free PMC article.

• Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy.

  Ortega Á, Salazar J, Galban N, Rojas M, Ariza D, Chávez-Castillo M, Nava M, Riaño-Garzón ME, Díaz-Camargo EA, Medina-Ortiz O, Bermúdez V. Ortega Á, et al. Int J Mol Sci. 2022 Apr 11;23(8):4196. doi: 10.3390/ijms23084196. Int J Mol Sci. 2022. PMID: 35457014 Free PMC article. Review.

• Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression.

  Leuchter AF, Hunter AM, Tartter M, Cook IA. Leuchter AF, et al. Br J Psychiatry. 2014 Dec;205(6):443-9. doi: 10.1192/bjp.bp.113.140343. Epub 2014 Sep 11. Br J Psychiatry. 2014. PMID: 25213159 Free PMC article. Clinical Trial.

• Brain and disease: the long path to discovery and treatment.

  Miksys SL, Tyndale RF. Miksys SL, et al. Clin Pharmacol Ther. 2009 Oct;86(4):343-6. doi: 10.1038/clpt.2009.168. Clin Pharmacol Ther. 2009. PMID: 19763109 Free PMC article. No abstract available.

• Brain structural properties predict psychologically mediated hypoalgesia in an 8-week sham acupuncture treatment for migraine.

  Liu J, Mu J, Liu Q, Dun W, Zhang M, Tian J. Liu J, et al. Hum Brain Mapp. 2017 Sep;38(9):4386-4397. doi: 10.1002/hbm.23667. Epub 2017 Jun 13. Hum Brain Mapp. 2017. PMID: 28608601 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information